9. Tuohy TM, Rowe KG, Mineau GP, et al. Risk of colorectal cancer and
adenomas in the families of patients with adenomas: a population-based study in Utah. Cancer 2014;120: 35–42.
10. Choi Y, Sateia HF, Peairs KS, Stewart RW. Screening for colorectal
cancer. Semin Oncol 2017; 44:34–44.
11. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal
cancer after excision of rectosigmoid adenomas. N Engl J Med
12. Rutter MD. Surveillance programmes for neoplasia in colitis. J Gastroenterol 2011;46 Suppl 1: 1–5.
13. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol
Clin North Am 2002;31:925–43.
14. Michels KB, Fuchs GS, Giovannucci E, et al. Fiber intake and incidence of colorectal cancer among 76,947 women and 47,279 men.
Cancer Epidemiol Biomarkers Prev 2005;14:842–9.
15. Omata F, Brown WR, Tokuda Y, et al. Modifiable risk factors
for colorectal neoplasms and hyperplastic polyps. Intern Med
16. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer
17. Aleksandrova K, Pischon T, Jenab M, et al. Combined impact of
healthy lifestyle factors on colorectal cancer: a large European cohort
study. BMC Med 2014;12:168.
18. Hermanek P, Wittekind C. The pathologist and the residual tumor
(R) classification. Pathol Res Pract 1994;190:115–23.
19. Lehnert T, Methner M, Pollok A, et al. Multivisceral resection for
locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg 2002;235:217–25.
20. Feinberg AE, et al. Oncologic outcomes following laparoscopic versus
open resection of p T4 colon cancer: a systematic review and meta-analysis. Dis Colon Rectum 2017;60:116–125.
21. Vignali A, et al. Laparoscopic treatment of advanced colonic cancer:
a case-matched control with open surgery. Colorectal Dis 2013;15:
22. Gainant A. Emergency management of acute colonic cancer obstruction. J Visc Surg 2012;149: e3–e10.
23. Rosenman LD. Hartmann’s operation. Am J Surg 1994;168:283–4.
24. Lee-Kong S, Lisle D. Surgical management of complicated colon
cancer. Clin Colon Rectal Surg 2015;28:228–33.
25. Bertelsen CA. Complete mesocolic excision an assessment of feasibility and outcome. Dan Med J 2017;64( 2).
26. Wolff WI SH. Definitive treatment of “malignant” polyps of the colon.
Ann Surg 1975;182:516–25.
27. Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent DJ, Wieand HS, et al. A comparison of laparoscopically assisted
and open colectomy for colon cancer. N Engl J Med 2004;350:2050– 9.
28. Gunderson LL, Jessup JM, Sarjent DJ, et al. Revised tumor and node
categorization for rectal cancer based on surveillance, epidemiology,
and end results and rectal pooled analysis outcomes. J Clin Oncol
29. Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology
and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers
30. Alves A, Panis Y, Mathieu P, et al. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a
prospective multicenter study. Arch Surg 2005;140:278–83.
31. Popescu RA, Norman A, Ross PJ, et al, Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin
32. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the
efficacy of newer adjuvant therapies in patients with stage II/III
colon cancer: findings from the ACCENT database. J Clin Oncol
33. Tominaga T, Nonaka T, Sumida Y, et al. Effectiveness of adjuvant che-
motherapy for elderly patients with lymph node-positive colorectal
cancer. World J Surg Oncol 2016;14:197.
34. Bos AC, van Erning FN, van Gestel YR, et al. Timing of adjuvant che-
motherapy and its relation to survival among patients with stage III
colon cancer. Eur J Cancer 2015;51:2553–61.
35. Peixoto RD, Kumar A, Speers C, et al. Effect of delay in adjuvant oxali-
platin-based chemotherapy for stage III colon cancer. Clin Colorectal
Cancer 2015;14: 25–30.
36. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in
colorectal cancer. College of American Pathologists Consensus State-
ment 1999. Arch Pathol Lab Med 2000;124:979–94.
37. Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and
surgical cytoreduction for poorly differentiated and signet ring cell
adenocarcinomas of the appendix. Ann Oncol 2012;23:652–8.
38. Krasna MJ, Flancbaum L, Cody RP, et al. Vascular and neural inva-
sion in colorectal carcinoma. Incidence and prognostic significance.
39. Cianchi F, Palomba A, Boddi V, et al. Lymph node recovery from
colorectal tumor specimens: recommendation for a minimum num-
ber of lymph nodes to be examined. World J Surg 2002;26:384–9.
40. Yoshimatsu K, et al. How many lymph nodes should be examined in
Dukes’ B colorectal cancer? Determination on the basis of cumulative
survival rate. Hepatogastroenterology 2005;52:1703–6.
41. Caplin S, Cerottini JP, Bosman FT, et al. For patients with Dukes’ B
(TNM Stage II) colorectal carcinoma, examination of six or fewer
lymph nodes is related to poor prognosis. Cancer 1998;83:666–72.
42. Veronese N, Nottegar A, Pea A, et al. Prognostic impact and implica-
tions of extracapsular lymph node involvement in colorectal cancer:
a systematic review with meta-analysis. Ann Oncol 2016;27: 42–8.
43. Li J, Yang S, Hu J, et al. Tumor deposits counted as positive lymph
nodes in TNM staging for advanced colorectal cancer: a retrospective
multicenter study. Oncotarget 2016;7:18269–79.
44. Venook A, Niedzwiecki D, Innocenti Fet al. Impact of primary (1º)
tumor location on overall survival (OS) and progression-free survival
(PFS) in patients (pts) with metastatic colorectal cancer (mCRC):
Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34
no. 15 suppl. Abstract 3504.
45. Schrag D, Brooks G, Meyerhardt JA ,et al. The relationship between
primary tumor sidedness and prognosis in colorectal cancer. J Clin
Oncol 2016; 34 no. 15 suppl. Abstract 3505.
46. Larrea AA, Lujan SA, Kunkel TA. SnapShot: DNA mismatch repair.
Cell 2010;141:730 e1.
47. Jass JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann
N Y Acad Sci 2000;910:62–73.
48. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer
(Lynch syndrome). An updated review. Cancer 1996;78:1149–67.
49. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis
of familial colorectal cancer. Science 1993;260:812–6.
50. Chen W, Swanson BJ, Frankel WL. Molecular genetics of micro-satellite-unstable colorectal cancer for pathologists. Diagn Pathol
51. Bupathi M, Wu C. Biomarkers for immune therapy in colorectal
cancer: mismatch-repair deficiency and others. J Gastrointest Oncol
52. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite
instability and colorectal cancer prognosis. J Clin Oncol 2005;23:
53. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and
clinical outcome in young patients with colorectal cancer. N Engl J